LRMR

Larimar Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · larimartx.com

$4.22

Mkt Cap $361.1M

52w Low $1.73 53.1% of range 52w High $6.42

50d MA $4.72 200d MA $4.00

P/E (TTM) -1.7x

EV/EBITDA -1.1x

P/B 3.7x

Debt/Equity 0.1x

ROE -212.2%

P/FCF -2.5x

RSI (14) —

ATR (14) —

Beta 1.02

50d MA $4.72

200d MA $4.00

Avg Volume 4.2M

About

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
May 4, 2026	BMO	—	—	—	3.94	-0.5%	—	—	—	—	—	—	—
Mar 19, 2026	BMO	-0.44	-0.73	-65.9%	4.30	-0.7%	+4.0%	+4.4%	+8.8%	+6.3%	+8.8%	+11.9%	—
Nov 5, 2025	BMO	-0.39	-0.61	-56.4%	3.80	-4.2%	-15.3%	-8.7%	-8.9%	-6.6%	-4.5%	-2.6%	—
Aug 14, 2025	BMO	-0.47	-0.41	+12.8%	3.72	-0.3%	+14.5%	+7.8%	+4.8%	-1.9%	+1.3%	+6.5%	—
Apr 30, 2025	BMO	-0.42	-0.46	-9.5%	2.39	+0.4%	+10.9%	+19.7%	+24.3%	+12.6%	-12.1%	-5.9%	—
Mar 24, 2025	BMO	-0.29	-0.45	-55.2%	2.54	+2.4%	-10.2%	-9.1%	-11.4%	-5.5%	-7.5%	-11.0%	—
Oct 30, 2024	BMO	-0.37	-0.24	+35.1%	7.78	+5.3%	+8.7%	+5.8%	-0.5%	-2.7%	-5.4%	-18.6%	—
Aug 7, 2024	BMO	-0.32	-0.34	-6.2%	7.65	+1.0%	-6.5%	-2.7%	+0.4%	-0.4%	-1.0%	+5.2%	—
May 9, 2024	BMO	-0.24	-0.27	-12.5%	7.92	-1.3%	-0.8%	-10.1%	-7.6%	-0.5%	-0.6%	+21.5%	—
Mar 14, 2024	BMO	-0.25	-0.30	-20.0%	9.30	-2.6%	-6.5%	-6.5%	-10.2%	-7.6%	-8.3%	-21.5%	—
Nov 14, 2023	BMO	-0.23	-0.21	+8.7%	2.39	+0.4%	+7.1%	+22.6%	+29.3%	+37.7%	+31.4%	+77.0%	—
Aug 10, 2023	BMO	-0.21	-0.19	+9.5%	4.00	+2.2%	-4.8%	-2.5%	+5.8%	+4.5%	+0.2%	-4.5%	—
May 15, 2023	BMO	-0.25	-0.15	+40.0%	5.06	-20.4%	-29.1%	-27.9%	-27.1%	-25.5%	-27.7%	-27.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 20	Wedbush	Maintains	Outperform → Outperform	—	$4.47	$4.52	+1.1%	+0.4%	+4.7%	+2.2%	+4.7%	+8.5%
Mar 3	Wedbush	Maintains	Outperform → Outperform	—	$5.23	$5.58	+6.7%	+5.4%	+4.2%	-0.2%	-0.2%	+8.8%
Feb 25	Wedbush	Maintains	Outperform → Outperform	—	$3.69	$3.66	-0.8%	+61.2%	+49.6%	+43.9%	+41.7%	+49.3%
Feb 25	Citigroup	Maintains	Buy → Buy	—	$3.69	$3.66	-0.8%	+61.2%	+49.6%	+43.9%	+41.7%	+49.3%
Oct 2	Oppenheimer	Maintains	Outperform → Outperform	—	$4.15	$4.22	+1.7%	+3.1%	+17.3%	+15.9%	+13.7%	+16.1%
Sep 30	Baird	Maintains	Outperform → Outperform	—	$3.38	$3.33	-1.5%	-4.4%	+22.8%	+26.6%	+44.1%	+42.3%
Sep 30	Wedbush	Maintains	Outperform → Outperform	—	$3.38	$3.33	-1.5%	-4.4%	+22.8%	+26.6%	+44.1%	+42.3%
Aug 19	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$3.90	$3.96	+1.5%	-6.4%	-3.3%	-5.4%	+0.3%	-4.6%
Aug 15	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$4.26	$4.32	+1.4%	-5.9%	-8.5%	-14.3%	-11.5%	-13.4%
Jun 25	Guggenheim	Maintains	Buy → Buy	—	$2.99	$3.04	+1.7%	+8.7%	+3.0%	+1.3%	-3.3%	-3.7%
Jun 24	Wedbush	Maintains	Outperform → Outperform	—	$2.42	$2.56	+5.8%	+23.6%	+34.3%	+27.3%	+25.2%	+19.4%
Jun 24	Guggenheim	Maintains	Buy → Buy	—	$2.42	$2.56	+5.8%	+23.6%	+34.3%	+27.3%	+25.2%	+19.4%
Mar 25	Baird	Maintains	Outperform → Outperform	—	$2.28	$2.28	+0.0%	+1.3%	-1.3%	+5.3%	+3.1%	-5.7%
Mar 25	Guggenheim	Maintains	Buy → Buy	—	$2.28	$2.28	+0.0%	+1.3%	-1.3%	+5.3%	+3.1%	-5.7%
Mar 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.28	$2.28	+0.0%	+1.3%	-1.3%	+5.3%	+3.1%	-5.7%
Jan 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.63	$3.73	+2.8%	-1.4%	-4.7%	-4.1%	+2.2%	+9.4%
Dec 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.83	$4.71	-2.5%	-10.6%	-13.9%	-17.6%	-17.0%	-18.0%
Dec 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.17	$3.95	-36.0%	-21.7%	-30.0%	-32.6%	-35.5%	-35.0%
Nov 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.69	$6.53	-2.4%	-7.9%	-4.6%	-9.1%	-8.4%	-7.9%
Oct 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.46	$8.47	+0.1%	-2.7%	-8.5%	-10.5%	-13.0%	-3.5%
May 31	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$7.10	$7.39	+4.1%	+12.7%	+28.7%	+33.9%	+39.3%	+33.8%
May 22	Citigroup	Maintains	Buy → Buy	—	$7.89	$7.89	+0.0%	+0.1%	-5.3%	-10.3%	-6.5%	-10.4%
May 21	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$7.27	$8.05	+10.7%	+8.5%	+8.7%	+2.8%	-2.6%	+1.5%
Mar 15	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$8.70	$8.41	-3.3%	+0.0%	-4.0%	-1.3%	-2.0%	-1.6%
Mar 12	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$8.63	$8.81	+2.1%	+1.6%	+7.8%	+0.8%	+0.8%	-3.2%
Feb 13	Citigroup	Maintains	Buy → Buy	—	$7.83	$8.06	+2.9%	+11.6%	+52.7%	+69.6%	+63.2%	+54.0%
Feb 13	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$7.83	$8.06	+2.9%	+11.6%	+52.7%	+69.6%	+63.2%	+54.0%
Nov 17	Citigroup	Upgrade	Neutral → Buy	—	$3.09	$3.25	+5.2%	+6.5%	+1.6%	-0.3%	+7.4%	+13.3%
Aug 15	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$4.23	$4.20	-0.7%	-1.2%	-5.2%	-6.6%	-8.5%	-6.6%
Jun 20	JMP Securities	Maintains	Market Outperform → Outperform	—	$3.30	$3.30	+0.0%	+5.5%	+5.2%	+1.8%	+0.3%	-1.5%
Jun 8	Citigroup	Maintains	Neutral → Neutral	—	$3.70	$3.71	+0.3%	-5.1%	-1.4%	+2.2%	+0.5%	-0.3%
May 18	Citigroup	Maintains	Neutral → Neutral	—	$3.69	$3.61	-2.2%	+2.2%	-0.8%	-1.6%	-1.9%	-0.8%
May 17	Guggenheim	Maintains	Buy → Buy	—	$3.65	$3.74	+2.5%	+1.1%	+3.3%	+0.3%	-0.5%	-0.8%
May 16	JMP Securities	Maintains	Market Outperform → Outperform	—	$3.59	$3.60	+0.3%	+1.7%	+2.8%	+5.0%	+1.9%	+1.1%
May 16	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$3.59	$3.60	+0.3%	+1.7%	+2.8%	+5.0%	+1.9%	+1.1%
May 15	Citigroup	Maintains	Neutral → Neutral	—	$5.06	$4.03	-20.4%	-29.1%	-27.9%	-27.1%	-25.5%	-27.7%
Mar 15	Guggenheim	Maintains	Buy → Buy	—	$5.90	$5.87	-0.5%	-1.9%	-0.8%	-8.8%	-18.1%	-19.5%
Mar 14	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$5.73	$5.98	+4.4%	+3.0%	+1.0%	+2.1%	-6.1%	-15.7%
Mar 1	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$6.06	$6.44	+6.3%	-4.0%	+4.0%	+3.3%	-1.8%	-2.1%
Jan 24	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$4.24	$4.24	+0.0%	+0.0%	+0.5%	-0.9%	+10.1%	+13.9%
Dec 13	Citigroup	Maintains	Neutral → Neutral	—	$3.89	$3.93	+1.0%	+2.1%	+15.2%	+17.2%	+15.2%	+29.8%
Oct 19	Guggenheim	Maintains	Buy → Buy	—	$3.45	$3.59	+4.1%	-0.6%	-3.5%	-2.9%	-15.1%	-13.3%
Sep 19	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$3.20	$3.46	+8.1%	+0.6%	+0.3%	+7.8%	+1.9%	+8.1%
Sep 19	William Blair	Upgrade	Market Perform → Outperform	—	$3.20	$3.46	+8.1%	+0.6%	+0.3%	+7.8%	+1.9%	+8.1%
Feb 15	William Blair	Downgrade	Outperform → Market Perform	—	$8.37	$3.05	-63.6%	-52.1%	-52.9%	-53.4%	-55.6%	-56.4%
Feb 1	William Blair	Maintains	Outperform → Outperform	—	$15.71	$16.31	+3.8%	+8.2%	+20.8%	+25.1%	+20.4%	+18.0%

Recent Filings

8-K

Unknown — 8-K Filing

Larimar reported 2025 results as a clinical-stage biotech with no approved products, making cash burn and upcoming financing needs critical metrics that will likely determine stock viability through key development milestones.

Mar 19

8-K · 8.01 !! High

Larimar Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement

Larimar Therapeutics updated its investor presentation, signaling ongoing engagement with capital markets stakeholders regarding company strategy and operational developments.

Mar 9

8-K

Larimar Therapeutics, Inc. -- 8-K Filing

Larimar Therapeutics completed a securities offering with Citizens JMP Securities as lead manager and JonesTrading as co-manager, indicating the company raised capital through institutional channels.

Feb 27

8-K · 8.01 !! High

Larimar Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement

Larimar Therapeutics received FDA Breakthrough Therapy Designation for nomlabofusp treating Friedreich's ataxia, accelerating development and review timelines for this rare genetic neurological disorder therapy.

Feb 24

Data updated apr 25, 2026 7:52pm · Source: massive.com